High-Expression, Rapid Production of Influenza Vaccines in Cell-Based Systems

在细胞系统中高表达、快速生产流感疫苗

• 批准号: 8075922
• 负责人: Pamuk Bilsel
• 金额: $ 32.04万
• 依托单位: CDI BIOSCIENCE, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8075922
• 关键词: Agglutinins; Apoptosis; Binding; Biomass; Bioreactors; Cell Culture Techniques; Cell Density; Cell Line; Cell Survival; Cell division; Cell membrane; Cells; Chemicals; Chickens; Chinese Hamster Ovary Cell; Culture Media; Disease Outbreaks; Engineering; Environment; Feeds; Fluorescein; Hour; Influenza A Virus, H1N1 Subtype; Isopropyl Thiogalactoside; Label; Legal patent; Length; Mammalian Cell; Measures; Methods; Monitor; Production; Protein Secretion; Proteins; Protocols documentation; Reaction Time; Risk; Staging; Surface; System; Technology; Time; Vaccine Production; Vaccines; Viral; Virus; Virus Diseases; Virus Receptors; base; bioprocess; cell growth; cellular engineering; cost; egg; expression vector; falls; feeding; feeding schedule; flasks; flexibility; influenza outbreak; influenza virus vaccine; influenzavirus; innovation; meetings; new technology; pandemic disease; receptor; receptor expression; scale up

DESCRIPTION (provided by applicant): We propose to develop an innovative high-expression CHO cell based platform for rapid Influenza vaccine production, which will have the ability to complete a 12 week vaccine production cycle, leading to a drastic reduction in response time to Influenza outbreak. This system will have advantages over the traditional approach to vaccine production in chicken eggs in that it can more feasibly meet the rapid "surge capacity" needs that would be required during a pandemic outbreak. Traditional methods of generating Influenza vaccines in embryonated chicken eggs fall short of the needs during a pandemic because of lengthy times required for scale-up, high costs, limited quantities of specialized eggs and potential risks of contamination. Cell-culture based vaccines are potentially a more reliable, flexible, and easily scalable method of producing vaccines; however, cell lines available for efficient large-scale vaccine production are limited. The approach is to integrate two novel technologies for creating a highly efficient, rapid vaccine production system within mammalian cells. The first technology, developed by FluGen, increases the number of surface bound influenza virus receptors for expanding the amount of virus that can infect the cell. The second technology, developed by CDI Bioscience, is incorporated into a high-expression mammalian host cell line (PACE") that, when activated, will be capable of more than doubling the expression of the surface receptors of the FluGen technology. We will achieve the objectives of the project by pursuing three specific aims over a three year period: (Aim 1) Develop a PACE" cell line that stably expresses FluGen surface receptors on cell membrane; Three to four high-expressing PACE" clonal lines stably expressing FluGen surface receptors on cell membrane will be developed. These clonal cell lines will be considered suitable for further characterization if they (a) show over 2-fold FluGen surface receptors expression upon RP shift; and (b) produce higher viral titers when infected with H1N1 (A/PR/8/34 strain) virus, as compared to the PACE" cells that are not engineered with the FluGen surface receptors. (Aim 2) Develop bioprocess protocols for influenza virus production in FluGen surface receptors expressing PACE" cells in shake flasks; We will determine the best CD medium for cell growth and culture viability, and the optimal VCD for induction of RP shift(R). We will then determine the best medium/feed/supplements combination that achieves: (a) at least 2-fold higher expression of FluGen surface receptors upon induction of RP shift(R). (2) Virus titers of at least 107-108 pfu/ml. (Aim 3) Develop scalable bioprocess protocols for influenza virus production in bench top and industrial bioreactors (50-100L); Adapted cells and optimal conditions from Aim 2 will be used in small-scale bench top bioreactors to determine the best cell growth and induction conditions in order to achieve the highest viral titer in an industrial environment. Subsequently, we will develop scale up strategy for optimal influenza virus production in 50-100L bioreactor. Narrative Traditional methods of generating Influenza vaccines in embryonated chicken eggs fall short of the needs during a pandemic outbreak. This project combines two novel technologies for creating a highly efficient, rapid vaccine production system within mammalian cells, allowing completion of a 12 week vaccine production cycle. Achieving the objectives of this project will form a major milestone towards leading to a drastic reduction in response time to Influenza outbreak.

描述（由申请人提供）：我们建议开发一种基于创新型高表达 CHO 细胞的平台，用于快速生产流感疫苗，该平台将能够完成 12 周的疫苗生产周期，从而大幅缩短对流感的反应时间暴发。该系统比传统的鸡蛋疫苗生产方法具有优势，因为它可以更切实地满足大流行爆发期间所需的快速“激增产能”需求。用含胚鸡蛋生产流感疫苗的传统方法无法满足大流行期间的需求，因为扩大规模所需的时间长、成本高、专用鸡蛋数量有限以及潜在的污染风险。基于细胞培养的疫苗可能是一种更可靠、灵活且易于扩展的疫苗生产方法；然而，可用于高效大规模疫苗生产的细胞系是有限的。该方法是整合两种新技术，在哺乳动物细胞内创建高效、快速的疫苗生产系统。第一项技术由 FluGen 开发，增加了表面结合的流感病毒受体的数量，以扩大可以感染细胞的病毒数量。第二种技术由 CDI Bioscience 开发，被整合到高表达哺乳动物宿主细胞系（PACE”）中，该细胞系在激活后能够使 FluGen 技术的表面受体表达量增加一倍以上。我们将实现该项目的目标是在三年内实现三个具体目标：（目标1）开发在细胞膜上稳定表达FluGen表面受体的PACE细胞系；将开发三到四个在细胞膜上稳定表达 FluGen 表面受体的高表达 PACE" 克隆系。如果这些克隆细胞系 (a) 在 RP 转换时显示出超过 2 倍的 FluGen 表面受体表达，则将被认为适合进一步表征；和（b）与未用 FluGen 表面受体改造的 PACE 细胞相比，感染 H1N1（A/PR/8/34 株）病毒时产生更高的病毒滴度。 （目标 2）制定在摇瓶中表达 PACE" 细胞的 FluGen 表面受体中生产流感病毒的生物工艺方案；我们将确定用于细胞生长和培养活力的最佳 CD 培养基，以及用于诱导 RP shift(R) 的最佳 VCD。然后，我们将确定最佳的培养基/饲料/补充剂组合，以实现： (a) 在诱导 RP shift(R) 后，FluGen 表面受体的表达至少提高 2 倍 (2) 病毒滴度至少为 2。 107-108 pfu/ml（目标 3）开发用于台式和工业生物反应器（50-100L）中流感病毒生产的可扩展生物工艺方案；目标 2 中的适应细胞和最佳条件将用于小型台式生物反应器确定最佳的细胞生长和诱导条件，以便在工业环境中实现最高的病毒滴度。随后，我们将制定最佳流感病毒生产的放大策略。 50-100L 生物反应器。 叙述 用含胚鸡蛋生产流感疫苗的传统方法无法满足大流行爆发期间的需求。该项目结合了两项新技术，在哺乳动物细胞内创建高效、快速的疫苗生产系统，从而完成 12 周的疫苗生产周期。实现该项目的目标将成为大幅缩短流感爆发响应时间的一个重要里程碑。